AZD-4818

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2010 - "Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. "
2.	Multiple Sclerosis 01/01/2010 - "Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. "
3.	Rheumatoid Arthritis 01/01/2010 - "Over the last several years, several of these antagonists entered clinical trials, including CP-481,715 (Pfizer) and MLN3897 (Millennium) for rheumatoid arthritis, BX471 (Berlex / Scherring AG) for multiple sclerosis, and AZD-4818 (Astra-Zeneca) for COPD. "

1.	quinoxaline-2-carboxylic acid (4- carbamoyl- 1- (3- fluorobenzyl)- 2,7- dihydroxy- 7- methyloctyl)amide
2.	BX 471
3.	MLN3897